India Continuous Glucose Monitoring (CGM) Market - 2024-2031

The India continuous glucose monitoring (CGM) market reached US$ 196.81 million in 2023 and is expected to reach US$ 510.73 million by 2031, growing at a CAGR of 12.4 % during the forecast period 2024-2031.

Continuous glucose monitoring (CGM) is an advanced technology that enables individuals, particularly those with diabetes, to continuously track their blood glucose levels throughout the day and night. CGM systems consist of a small sensor that is inserted under the skin, which measures glucose levels in the interstitial fluid. This data is then transmitted to a receiver or smartphone app, providing real-time insights into glucose trends and allowing users to make informed decisions regarding their health management.

India continuous glucose monitoring (CGM) provides continuous data on glucose levels, enabling users to observe fluctuations throughout the day. Many CGM systems are equipped with alerts for high or low glucose levels, assisting users in taking timely actions to prevent complications. The collected data can be accessed through smartphones or dedicated devices, offering easy visibility into trends and patterns over time. Some continuous glucose monitoring (CGM) can connect with insulin pumps and mobile health applications, facilitating comprehensive diabetes management. These factors have driven India continuous glucose monitoring (CGM) market expansion.

Market Dynamics: Drivers & Restraints

Rising Prevalence of Diabetes

The rising prevalence of diabetes is significantly driving the growth of the India continuous glucose monitoring (CGM) market and is expected to drive throughout the market forecast period.

Diabetes is a chronic condition that arises when the pancreas fails to produce sufficient insulin or when the body cannot effectively utilize the insulin it produces. Insulin is a crucial hormone responsible for regulating blood sugar levels. When diabetes is uncontrolled, it can lead to hyperglycemia, or elevated blood sugar levels, which over time can cause serious damage to various bodily systems, particularly affecting nerves and blood vessels.

According to the World Health Organization (WHO) data, in India, it is estimated that approximately 77 million adults over the age of 18 are living with type 2 diabetes, while nearly 25 million individuals are classified as prediabetic, placing them at a higher risk of developing diabetes shortly. Alarmingly, more than 50% of these individuals are unaware of their diabetic status, which can lead to significant health complications if the condition remains undiagnosed and untreated. All these factors demand India continuous glucose monitoring (CGM) market growth.

Furthermore, key players in the industry research studies and product launches that would drive the India continuous glucose monitoring (CGM) market growth. For instance, in September 2024, Trinity Biotech plc, a company specializing in human diagnostics and diabetes management solutions, announced plans to conduct an in-country study in India as part of its global launch strategy for its next-generation Continuous Glucose Monitoring (CGM) technology. This initiative aims to gather valuable feedback from diabetes patients and healthcare professionals in India to refine the product specifically for the Indian market.

Also, in March 2022, Medtronic India announced the launch of the MiniMed 780G system, a next-generation closed-loop insulin pump designed specifically for the treatment of type 1 diabetes in individuals aged 7 to 80 years. This innovative system leverages Medtronic's advanced SmartGuard technology, which automates the delivery of both basal insulin and correction boluses every five minutes. This automation aims to help individuals with diabetes avoid both high and low blood sugar levels more easily. All these factors demand India continuous glucose monitoring (CGM) market growth.

Moreover, the rising demand for the development of personalized medicine contributes to India continuous glucose monitoring (CGM) market expansion.

High Cost of CGM Devices

The high cost of India continuous glucose monitoring (CGM) systems can be prohibitively high for many patients, especially in a country where a substantial portion of the population lacks access to adequate healthcare resources. The initial investment required for the device, along with the ongoing expenses for sensor replacements, can discourage patients from adopting this technology, thereby limiting its market penetration.

The India continuous glucose monitoring (CGM) market faces significant challenges due to the high costs associated with CGM systems, which can deter many potential users. For instance, Abbott's FreeStyle Libre System is priced at approximately ₹11,000 for the reader and biosensor, with the sensor costing around ₹5,000 and providing continuous readings for 14 days. This recurring expense can be a financial burden for many consumers, especially in a country where many individuals live on limited incomes.

The initial investment required for CGM devices, combined with the ongoing costs of sensor replacements, poses a significant barrier to adoption. Many households may struggle to allocate funds for such advanced medical technology, particularly when basic healthcare needs are often unmet. As a result, the high price point limits market penetration and accessibility for individuals who could benefit from continuous glucose monitoring. Thus, the above factors could be limiting the India continuous glucose monitoring (CGM) market's potential growth.

Segment Analysis

The India continuous glucose monitoring (CGM) market is segmented based on component, application, and end-user.

Component:

The sensors segment is expected to dominate the India continuous glucose monitoring (CGM) market share

The sensors segment holds a major portion of the India continuous glucose monitoring (CGM) market share and is expected to continue to hold a significant portion of the India continuous glucose monitoring (CGM) market share during the forecast period.

Sensors are fundamental elements of continuous glucose monitoring (CGM) systems, designed to continuously measure glucose levels in the interstitial fluid beneath the skin. By providing real-time data, these sensors enable users to monitor their blood glucose levels throughout the day and night, eliminating the need for frequent finger-prick tests.

The sensors utilized in India continuous glucose monitoring (CGM) systems typically consist of a small electrode that measures glucose levels. They are inserted under the skin and can function for several days before needing replacement. Notable instances available in the Indian market include the FreeStyle Libre Pro Sensor Which operates for 14 days, the Dexcom G4 Sensor which functions for 10 days, and the Medtronic Guardian Sensor which lasts for 7 days.

Innovations in India continuous glucose monitoring (CGM) sensor technology are enhancing the accuracy, reliability, and usability of continuous glucose monitoring (CGM) devices. The rising prevalence of diabetes in India projected to reach approximately 101.2 million cases by 2030 is driving demand for effective monitoring solutions like continuous glucose monitoring (CGM). As awareness regarding diabetes management increases, more patients are seeking advanced technologies that provide better control over their condition. All these demand segment growth in the India continuous glucose monitoring (CGM) market.

Furthermore, as manufacturers continue to innovate and enhance sensor technology, this segment will play a vital role in improving patient outcomes and expanding access to India continuous glucose monitoring solutions across global. For instance, in November 2023, Abbott launched the FreeStyle LibreLink mobile app in India, a significant advancement in diabetes management technology.

This app allows users of the FreeStyle Libre system to monitor their glucose levels conveniently on their smartphones without the need for painful finger pricks. The FreeStyle LibreLink app enables users to view their glucose readings in real-time directly on compatible iPhone and Android smartphones. This eliminates the need for a separate reader device, making glucose monitoring more convenient and accessible. These factors have solidified the segment's position in the India continuous glucose monitoring (CGM) market.

Competitive Landscape

The major players in the India continuous glucose monitoring (CGM) market include Abbott, Dexcom, Inc., Medtronic Pvt. Ltd., Ascensia Diabetes Care Holdings AG., F. Hoffmann-La Roche Ltd, iHealth Labs Inc., Ypsomed AG, Medtrum Technologies Inc., Menarini Diagnostics s.r.l, and Nemaura among others.

Key Developments

• In February 2023, Dario Health Corp. announced a significant agreement with Dexcom, a leader in India continuous glucose monitoring (CGM) technology, to integrate Dexcom's CGM data into Dario's multi-chronic condition platform. This collaboration aims to enhance diabetes management by allowing users to seamlessly incorporate real-time glucose monitoring into their health management routines.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The India continuous glucose monitoring (CGM)market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Procedural Volume Assessment & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.